OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
3BBL56

3B Blackbio DX Ltd

Agricultural ChemicalsVerified

3B Blackbio DX maintains a strong liquidity position, with a current ratio of 7.11, indicating a high ability to meet short-term obligations. The company's liquidity risk is assessed as low, supported by INR 124.7 million in cash and equivalents and a free cash flow of INR 453.1 million. The capital structure is predominantly equity-based, with total equity of INR 2.68 billion and minimal long-term debt of INR 3.07 million. The company's profitability is robust, with a return on equity (ROE) of 17.77% and a return on assets (ROA) of 16.13%. These figures suggest that the company is effectively utilizing its equity and asset base to generate returns, outperforming the typical performance metrics for the Agricultural Chemicals industry. 3B Blackbio DX operates in two primary segments: Agrochemicals and Diagnostic kits. The diagnostic segment is the core of the company's operations, focusing on the design, development, and commercialization of qPCR tests, rapid tests, and NGS-based molecular diagnostic kits. The company's geographic exposure is primarily concentrated in India, with commercialization efforts directed toward domestic diagnostics labs. The company's growth trajectory is positive, with a strong revenue base of INR 964.7 million and a gross profit of INR 708.2 million. While specific future revenue projections are not provided, the company's current financial performance and market position suggest a stable growth outlook. Risk factors for 3B Blackbio DX are minimal, with low liquidity and dilution risks identified. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is assessed as low. The capital structure remains stable, with no significant changes in shares outstanding between basic and diluted shares. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company continues to focus on its core diagnostic and agrochemical segments, with no disclosed regulatory or operational disruptions.

30-day price · 3BBL-22.00 (-1.8%)
Low$1151.10High$1413.00Close$1202.70As of21 May, 00:00 UTC
Profile
Company3B Blackbio DX Ltd
Ticker3BBL.BO
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryAgricultural Chemicals
AI analysis

Business. 3B Blackbio DX Limited is an India-based company engaged in the development and commercialization of PCR-based molecular diagnostic kits and lateral flow assays, primarily serving the agrochemical and diagnostic markets.

Classification. 3B Blackbio DX is classified under the Basic Materials economic sector, Chemicals business sector, and Agricultural Chemicals industry, with a confidence level of 0.92.

3B Blackbio DX maintains a strong liquidity position, with a current ratio of 7.11, indicating a high ability to meet short-term obligations. The company's liquidity risk is assessed as low, supported by INR 124.7 million in cash and equivalents and a free cash flow of INR 453.1 million. The capital structure is predominantly equity-based, with total equity of INR 2.68 billion and minimal long-term debt of INR 3.07 million. The company's profitability is robust, with a return on equity (ROE) of 17.77% and a return on assets (ROA) of 16.13%. These figures suggest that the company is effectively utilizing its equity and asset base to generate returns, outperforming the typical performance metrics for the Agricultural Chemicals industry. 3B Blackbio DX operates in two primary segments: Agrochemicals and Diagnostic kits. The diagnostic segment is the core of the company's operations, focusing on the design, development, and commercialization of qPCR tests, rapid tests, and NGS-based molecular diagnostic kits. The company's geographic exposure is primarily concentrated in India, with commercialization efforts directed toward domestic diagnostics labs. The company's growth trajectory is positive, with a strong revenue base of INR 964.7 million and a gross profit of INR 708.2 million. While specific future revenue projections are not provided, the company's current financial performance and market position suggest a stable growth outlook. Risk factors for 3B Blackbio DX are minimal, with low liquidity and dilution risks identified. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is assessed as low. The capital structure remains stable, with no significant changes in shares outstanding between basic and diluted shares. Recent events and filings do not indicate any material changes in the company's operations or financial position. The company continues to focus on its core diagnostic and agrochemical segments, with no disclosed regulatory or operational disruptions.
Key takeaways
  • 3B Blackbio DX has a strong liquidity position with a current ratio of 7.11 and INR 124.7 million in cash and equivalents.
  • The company's profitability is robust, with ROE and ROA of 17.77% and 16.13%, respectively.
  • The diagnostic segment is the core of the company's operations, with a focus on PCR-based molecular diagnostic kits.
  • The company's growth trajectory is positive, supported by a strong revenue base and gross profit.
  • Risk factors are minimal, with low liquidity and dilution risks identified.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$964.7M
Gross profit$708.2M
Operating income$490.2M
Net income$476.9M
R&D
SG&A
D&A
SBC
Operating cash flow$433.6M
CapEx-$9.0M
Free cash flow$453.1M
Total assets$2.96B
Total liabilities$273.0M
Total equity$2.68B
Cash & equivalents$124.7M
Long-term debt$3.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.68B
Net cash$121.7M
Current ratio7.1
Debt/Equity0.0
ROA16.1%
ROE17.8%
Cash conversion91.0%
CapEx/Revenue-0.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
Metric3BBLActivity
Op margin50.8%0.4% medp25 -8.0% · p75 16.0%top quartile
Net margin49.4%2.3% medp25 -11.6% · p75 11.8%top quartile
Gross margin73.4%20.8% medp25 14.9% · p75 24.0%top quartile
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-0.9%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity0.0%59.0% medp25 54.9% · p75 72.9%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:24 UTC#8b6bc129
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 13:27 UTCJob: 7c79ab2f